AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Guardant Health Expands Cancer Test Access with PathGroup Deal
ByAinvest
Monday, Sep 8, 2025 9:07 am ET1min read
Guardant Health has expanded access to its cancer test, Shield, through a deal with PathGroup. The precision oncology company provides critical insights into cancer through blood and tissue tests, real-world data, and AI analytics. Its tests improve outcomes across all stages of care, including screening, monitoring, and treatment selection for patients with advanced cancer. Guardant360 is a comprehensive liquid biopsy test used as a companion diagnostic for NSCLC and breast cancer.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet